{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:10:44Z","timestamp":1790611844124,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bpobgyn.2023.102349","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T22:40:27Z","timestamp":1684363227000},"page":"102349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective"],"prefix":"10.1016","volume":"89","author":[{"given":"R.","family":"Matorras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.S.","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Schwarze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chang-Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iniesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"D'Hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2023.102349_bib1","series-title":"Infertility: key facts","year":"2020"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib2","series-title":"ICMART glossary. Infertility","year":"2023"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib3","series-title":"On infertility \u2013 prevalence, treatment and fertility decline in Europe","year":"2021"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib4","series-title":"Factsheet","year":"2022"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib5","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.18632\/aging.102497","article-title":"Global, regional, and national prevalence and disability-adjusted life-years for infertility in 195 countries and territories, 1990-2017: results from a global burden of disease study","volume":"11","author":"Sun","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib6","article-title":"European IVF monitoring consortium (EIM), for the European society of human reproduction and embryology (ESHRE)","volume":"2022","author":"Wyns","year":"2022","journal-title":"Hum Reprod Open"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib7","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/humrep\/deab198","article-title":"International committee for monitoring assisted reproductive technologies world report: assisted reproductive technology, 2014","volume":"36","author":"Chambers","year":"2021","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib11","author":"HFEA"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib12","series-title":"Assisted reproductive technology (ART) techniques","author":"Jain","year":"2022"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib13","doi-asserted-by":"crossref","first-page":"hoz044","DOI":"10.1093\/hropen\/hoz044","article-title":"Survey on ART and IUI: legislation, regulation, funding and registries in European countries: the European IVF-monitoring consortium (EIM) for the European society of human reproduction and embryology (ESHRE)","volume":"2020","author":"Calhaz-Jorge","year":"2020","journal-title":"Hum Reprod Open"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bpobgyn.2022.01.008","article-title":"Economic evaluation of Medically Assisted Reproduction: an educational overview of methods and applications for healthcare professionals","volume":"85","author":"Luyten","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bpobgyn.2022.10.003","article-title":"Valuing live births from assisted reproduction: a health economics viewpoint","volume":"85","author":"Martins","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bpobgyn.2022.02.002","article-title":"Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry","volume":"85","author":"B\u00fchler","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/IJWH.S193048","article-title":"A\u00a0cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany","volume":"11","author":"Xue","year":"2019","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bpobgyn.2022.01.011","article-title":"Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: a cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers","volume":"85","author":"Schwarze","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.fertnstert.2020.03.029","volume":"114","author":"Witz","year":"2020","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib20","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Andersen","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/IJWH.S118687","article-title":"A\u00a0cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility","volume":"8","author":"Gizzo","year":"2016","journal-title":"Int J Womens Health"},{"issue":"1","key":"10.1016\/j.bpobgyn.2023.102349_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12522-011-0097-2","article-title":"Gonadotropin stimulation: past, present and future","volume":"11","author":"Lunenfeld","year":"2011","journal-title":"Reprod Med Biol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fendo.2019.00429","article-title":"The development of gonadotropins for clinical use in the treatment of infertility","volume":"10","author":"Lunenfeld","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib25","series-title":"European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal products applications","year":"2019"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib26","series-title":"Biosimilar medicines: overview","year":"2022"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib27","series-title":"Reference product exclusivity for biological products filed under section 351(a) of the PHS Act: guidance for industry","year":"2014"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib28","series-title":"Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry","year":"2015"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib29","series-title":"Questions and answers on biosimilar development and the BPCI Act: guidance for industry","year":"2021"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034566","article-title":"Observational retrospective study of UK national success, risks and costs for 319,105 IVF\/ICSI and 30,669 IUI treatment cycles","volume":"10","author":"Bahadur","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib31","unstructured":"Passet-Wittig J, Ruckdeschel K, Schumann A, Bujard M, Wiesbaden: bundesinstitut f\u00fcr Bev\u00f6lkerungsforschung Policy Brief. URN: nbn:de:bib-var-2018-056."},{"key":"10.1016\/j.bpobgyn.2023.102349_bib32","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.3346\/jkms.2020.35.e341","article-title":"Socioeconomic status and successful delivery after an infertility diagnosis: a nationwide health insurance cohort study in Korea conducted from 2005 to 2013","volume":"35","author":"Shin","year":"2020","journal-title":"J\u00a0Kor Med Sci"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12939-021-01438-x","article-title":"Assisted reproduction in Spain, outcome and socioeconomic determinants of access","volume":"20","author":"Alon","year":"2021","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40258-022-00764-7","article-title":"What features of fertility treatment do patients value? Price elasticity and willingness-to-pay values from a discrete choice experiment","volume":"21","author":"Keller","year":"2023","journal-title":"Appl Health Econ Health Pol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib35","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/humrep\/dev163","article-title":"Economic aspects of infertility care: a challenge for researchers and clinicians","volume":"30","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib36","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/humrep\/den435","article-title":"Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK","volume":"24","author":"Connolly","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.rbms.2016.04.001","article-title":"Long-term fiscal implications of funding assisted reproduction: a generational accounting model for Spain","volume":"1","author":"Matorras","year":"2016","journal-title":"Reprod Biomed Soc Online"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0015-0282(02)04939-7","article-title":"Total reproductive potential of a single cycle--to include fresh and frozen embryos?","volume":"79","author":"Jones","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/humrep\/12.3.548","article-title":"Cryopreservation: a simplified method of evaluation","volume":"12","author":"Jones","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0303-7207(00)00357-9","article-title":"Evaluation of the clinical efficacy of embryo cryopreservation","volume":"169","author":"Schnorr","year":"2000","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib42","first-page":"1","article-title":"A\u00a0cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective","author":"Grynberg","year":"2018","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.bpobgyn.2023.102349_bib43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14737167.2021.1910026","article-title":"The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature","volume":"21","author":"\u0160prem Gold\u0161tajn","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693423000494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693423000494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:15:27Z","timestamp":1761498927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693423000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":38,"alternative-id":["S1521693423000494"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2023.102349","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2023.102349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102349"}}